Landscape of genetic lesions in 944 patients with myelodysplastic syndromes

Short summary

A large-scale genetic analysis of 944 myelodysplastic syndromes (MDS) patients identified mutations in 89.5% of cases, with TET2, SF3B1, ASXL1, SRSF2, DNMT3A, and RUNX1 being the most frequent. A novel prognostic model ('Model-1') incorporating 14 gene mutations and conventional factors accurately stratified patients into four distinct risk groups with significantly different 3-year survival rates (95.2% to 5.3%).

AI-generated from the title and abstract; the full text is not read.